Neonatal sepsis remains the major cause of mortality and morbidity including neurodevelopmental impairment and prolonged hospital stay in newborn infants. Despite of advances in technology and optimal antibiotic tre-atment, incidence of neonatal sepsis and its complications remains unacceptably high especially in developing countries. Premature neonates in particular are at higher risk due to developmentally immature host defence mecha-nisms. Though not approved by Food and Drug Administration (FDA) U.S.A, off label use of intravenous immunoglobulin as prophylactic or adjuvant agent in suspected or proven neonatal infections continues in many countries. In a recent large multicenter clinical trial by International Neonatal Immunotherapy Study (INIS) group, the use of polyvalent IgG immune globulin was not associated with significant differences in the risk of major com-plications or other adverse outcomes in neonates with suspected or proven sepsis. Hence, use of intravenous immu-noglobulin in suspected or proven neonatal sepsis is not recommended. The expense of prophylactic use of intrave-nous immunoglobulin administration for both term and preterm newborn population, given the minimal benefit as demonstrated by many individual studies and by meta-analysis is not justified.

[1] KLEIN J O.Bacteriology of neonatal sepsis[J].Pediatric Infectious Disease Journal,1990,9(10):777-78.
[2] FALCIGIA G,HAGEMAN J R,SCHREIBER M,et al.Antibiotic therapy and early onset sepsis[J].Neoreviews,2012,13(2):e86-89.
[3] HAQUE K N.Forfar and Arneil's textbook of Pediatrics[M].New York:Churchill Livingstone,1998:273-89.
[4] 金汉珍,黄德珉,官希吉.实用新生儿学[M].北京:人民卫生出版社,2002:342-349.
[5] Report of the National Neonatal Perinatal Database[M].National Neonatology Forum.India:Chetna Press,2002:e01-20.
[6] ZAIDI A K,GANATARA H A,SYED S,et al.Effect of case management on neonatal mortality due to sepsis and pneumonia[J].BMC Public Health,2011,11(Suppl 3):S13-13.
[7] Demographic and Health Survey.2011 Preliminary report[M].Govt.of Nepal:National Publications,2011:e36-36.
[8] UNICEF statistics Nepal,2011.http://www.unicef.org/infobycountry/nepal_nepal_statistics.html
[9] KOUTOUBY A,HABIBULLAH J.Neonatal sepsis in Dubai,United Arab Emirates[J].Trop Pediatr,1995,41(3):177-180.
[10] KIM K S.Use of intravenous immunoglobulin in the treatment of neonatal sepsis[J].Am J Dis Child,1989,143(11):1257-1258.
[11] FERRIERI P.Neonatal susceptibility and immunity to major bacterial pathogens[J].Rev Infect Dis,1990,12(Suppl 4):S394-400.
[12] OHLSSON A,LACY J B.Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants[J].The Cochrane Database of Systematic Reviews,2004,Issue 1,Art No:CD000361.
[13] STOLL B J,HANSEN N I,ADAMS-CHAPMAN I,et al.Neuro development and growth impairment among extremely low birth weight infants with neonatal infections[J].JAMA,2004,292(19):2357-2365.
[14] DAMMANN O,LEVITON A.Infections remote from brain; neonatal white matter damage and CP in preterm infants[J].Semin Pediatr Neurol,1998,5(3):190-201.
[15] MURPHY D J,SELLERS S,MACKENZIE I Z,et al.Case control study of ante-natal intra-partum risk for CP in very term preterm babies[J].Lancet,1995,346(8988):1449-1454.
[16] MITTENDORF R,COVERT R,KOHN J,et al.The association of CONS isolated from chorioamnion at delivery and subsequent development of CP[J].J Perinatology,2001,21(1):3-8.
[17] Clinical guidelines for immunoglobulin use[M].Second Edition Update.[s.l.]:Department of Health UK,2011:e4-6.
[18] OHLSSON A,LACY J B.Intravenous immunoglobulin for suspected or subsequently proven infection in neonates[J].Cochrane Database Syst Rev,2004(1):CD001239.
[19] CRISTINA M,NOVARETTI Z,DINARDO C L.Clinical applications of immunoglobulin:update[J].Rev Bras Hematol Hemoter,2011,33(3):221-230.
[20] FISCHER G W.Use of intravenous immune globulin in newborn infants[J].Clin Exp Immunol,1994,97(Suppl 1):73-77.
[21] 王东升,静滴丙种球蛋自治疗新生儿败血症疗效观察[J].中国社区医师:医学专业,2012,14(17):173-73.
[22] GAO J S.A clinical study of IVIG preventing the early newborn baby from infection[J].Journal of China Practical Medicine,2009,4(36):26-27.
[23] 李湘萍,静脉注射免疫球蛋白治疗低出生体重儿重症感染的疗效观察[J].北京医学,2012,34(7):626-626.
[24] 蒋惠芬,王淮燕,张琳,等.静脉丙种球蛋白预防早产儿感染的临床探讨[J].临床合理用药,2012,5(2B):30-31.
[25] ZHAO Y,WANG H Y,ZHANG L,et al.The clinical effects of intravenous immunoglobulin in treatment of very low birth weight infant[J].Medical Innovation of China,2012,9(2):16-17.
[26] FANAROFF A A,KORONES S B,WRIGHT L L,et al.A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants.National Institute of Child Health and Human Development Neonatal[JP4]Research Network[J].N Engl J Med,1994,330(16):1107-1113.
[27] OHLSSON A,LACY J B.Intravenous immunoglobulin for suspected or subsequently proven infection in neonates[J].Cochrane Database Syst Rev,2004,CD001239.
[28] BENJAMIN D K,SCHELONKA R,WHITE R,et al.A blinded,randomized,multicenter study of an intravenous Staphylococcus aureus immune globulin[J].J Perinatol,2006,26(5):290-295.
[29] DEJONGE M,BURCHFIELD D,BLOOM B,et al.Clinical tr-ial of safety and efficacy of INH-A21 for the prevention of no-socomial staphylococcal bloodstream infection in premature i-nfants[J].J Pediatr,2007,151(3):260-65.
[30] WEISMAN L E,THACKRAY H,STEINHORN R H,et al.A randomized study of a monoclonal antibody(pagibaximab) to prevent staphylococcal sepsis[J].Pediatrics,2011,128(2):271-278.
[31] HAQUE K N Use of intravenous immunoglobulin in the treatment of neonatal sepsis:A pragmatic review and analysis[J].Journal of Medical Sciences,2010,3(3):160-167.
[32] OHLSSON A,LACY J.Intravenous immunoglobulin for suspected or subsequently proven infection in neonates[J].Cochrane Database Syst Rev,2010,(3):CD001239.
[33] BROCKLEHURST P,FARRELL B,KING A,et al.INIS collaborative group,treatment of neonatal sepsis with intravenous immune globulin[J].N Engl J Med,2011,365(13):1201-1211.
[34] FRANCO A C,TORRICO A C,MORIERA F T,et al.Adjuvant use of intravenous immunoglobulin in the treatment of neonatal sepsis:a systematic review with a meta-analysis[J].J Pediatr(Rio J),2012,88(5):377-83.